Table 4

Adjusted rate ratios ofpneumonia associated with currentuse of pramipexole relativeto non-current use, stratifiedby history of pneumoniaprior to cohort entryand use of anti-parkinsonian medication prior tothe 180-day period beforethe index date
Cases Controls Adjusted* P-value for interaction
Rate ratio 95% CI
Number of subjects 1835 16088
 History of pneumonia 4/127 23/564 0.66 0.22 – 2.00 0.81
 No history of pneumonia 55/1708 711/15524 0.75 0.56 – 1.01
 Levodopa use 36/1524 461/13128 0.71 0.49 – 1.01 0.43
 No levodopa use 23/311 273/2960 0.90 0.55 – 1.45
 Any dopamine agonist use 46/437 602/3993 0.67 0.48 – 0.95 0.44
 No dopamine agonist use 13/1398 132/12095 0.89 0.47 – 1.66
 Ergot-derived dopamine agonist use 14/258 148/2082 0.69 0.38 – 1.24 0.80
 No ergot-derived dopamine agonist use 45/1577 586/14006 0.75 0.54 – 1.04

* Adjusted for current use of other dopamine agonists, other anti-parkinsonian drugs and selected.

factors from Table 1, namely age, duration of APK use, obesity, smoking, alcohol, cerebrovascular, ischemic heart disease, hypertension, heart failure, diabetes, edema, COPD, asthma, prior pneumonia, lung cancer, other cancer, depression, anemia, renal failure, vaccination (influenza and pneumonia), PPIs, NSAIDs, oral corticosteroids, other respiratory medications, antibiotics, antipsychotics and antidepressants.

‡ Current use refers to a prescription ending after or within 30 days prior to the index date.

‡ Previous timing of covariate refers to the period prior to 180 days before the index date.

Ernst et al.

Ernst et al. BMC Neurology 2012 12:113   doi:10.1186/1471-2377-12-113

Open Data